Stock Comparison

JNJ vs PBYI

Johnson & Johnson vs Puma Biotechnology Inc

The Verdict

PBYI takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

PBYI

Puma Biotechnology Inc

2.0

out of 10

Risk Trap

Head-to-Head

$557.1B

Market Cap

$382M

26.5

P/E Ratio

12.3

21.8%

Profit Margin

13.6%

26.3%

Return on Equity

27.8%

0.6

Debt-to-Equity

0.2

Conservative

Overall Risk

Aggressive

1.0

DVR Score

2.0

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

PBYI2.0/10

Puma Biotechnology remains a highly speculative investment with limited 10x growth potential within 3-5 years. While the company exhibits a strong balance sheet and explicitly positive TTM free cash flow ($41.73M), which provides financial stability, the core business faces significant headwinds. Previous intelligence indicated declining new prescriptions for NERLYNX and a projected revenue declin...

Full PBYI Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.